PMID- 35313528
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220323
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 15
DP  - 2022
TI  - A Novel LOC101927967 Intergenic Region ALK Fusion Identified by NGS and Validated 
      by IHC and FISH in a Patient with Early Stage Adenocarcinoma of Lung.
PG  - 251-254
LID - 10.2147/OTT.S347200 [doi]
AB  - Anaplastic lymphoma kinase (ALK) gene rearrangement is an essential driver 
      mutation identified in approximately 5% of non-small cell lung cancers (NSCLCs). 
      The results of clinical trials have demonstrated the impressive efficacy of ALK 
      tyrosine kinase inhibitors (ALK-TKIs). Besides the classic EML4-ALK fusions, a 
      growing list of gene fusion partners for ALK in NSCLC have been identified with 
      heterogeneous clinical responses to ALK-TKIs. However, a LOC101927967-ALK fusion 
      has not been reported in NSCLC. Herein, a novel LOC101927967 downstream 
      intergenic region ALK fusion in an early-stage patient with lung adenocarcinoma 
      was first identified by next-generation sequencing (NGS) and verified by 
      immunohistochemical staining (IHC) and fluorescence in situ hybridization (FISH), 
      which might provide a treatment option for postoperative recurrence.
CI  - (c) 2022 Jia et al.
FAU - Jia, Xiaojing
AU  - Jia X
AD  - Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, 
      People's Republic of China.
FAU - He, Qianru
AU  - He Q
AD  - The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, People's 
      Republic of China.
AD  - Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, People's Republic 
      of China.
AD  - The State Key Lab of Translational Medicine and Innovative Drug Development, 
      Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, People's Republic of China.
FAU - Xing, Xiaodan
AU  - Xing X
AD  - The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, People's 
      Republic of China.
AD  - Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, People's Republic 
      of China.
AD  - The State Key Lab of Translational Medicine and Innovative Drug Development, 
      Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, People's Republic of China.
FAU - Yang, Yanming
AU  - Yang Y
AD  - Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, 
      People's Republic of China.
FAU - Ma, Yan
AU  - Ma Y
AD  - Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, 
      People's Republic of China.
LA  - eng
PT  - Case Reports
DEP - 20220314
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC8933637
OTO - NOTNLM
OT  - ALK
OT  - intergenic fusion
OT  - lung cancer
COIS- The authors have no conflicts of interest to declare in this work.
EDAT- 2022/03/23 06:00
MHDA- 2022/03/23 06:01
PMCR- 2022/03/14
CRDT- 2022/03/22 05:06
PHST- 2021/11/29 00:00 [received]
PHST- 2022/03/07 00:00 [accepted]
PHST- 2022/03/22 05:06 [entrez]
PHST- 2022/03/23 06:00 [pubmed]
PHST- 2022/03/23 06:01 [medline]
PHST- 2022/03/14 00:00 [pmc-release]
AID - 347200 [pii]
AID - 10.2147/OTT.S347200 [doi]
PST - epublish
SO  - Onco Targets Ther. 2022 Mar 14;15:251-254. doi: 10.2147/OTT.S347200. eCollection 
      2022.